Schott Hungary has entered agreements with Strabag, Weinberg, and Szarnyas related to the construction of new production facilities in Lukacshaza, Hungary.
Schott is a provider of solutions and services to the pharmaceutical and biotechnology industries. According to the company, it “is investing more than 100 million euros in its existing site in Lukacshaza, Hungary, to expand its capacity for sterile ready-to-use cartridges. Following the opening of a new facility for pre-fillable glass syringes at the site in 2024, the company has now broken ground for another facility that will add further manufacturing capacity for high-value solutions.
“To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields. That is why we are investing more than 100 million euros in our plant in Hungary,” said Andreas Reisse, CEO of Schott Pharma. “RTU cartridges are used to store biologics, GLP-1 drugs, insulin, or hormone therapies to treat diabetes, obesity, or other immunological diseases. The new facility will bring over 100 additional jobs to the region.”
“We would like to express our sincerest gratitude to the Ministry of Foreign Affairs and Trade for its support of these two expansion projects,” added Eva Szabo, Site Manager Lukacshaza. “Lukacshaza is not only an important location for ensuring supply security to customers in the region but also makes an important contribution to Schott Pharma’s global growth strategy.”
